SIRPA and cancer: Therapeutic antibodies and a SIRPα-Fc fusion decoy designed to block the interaction between CD47 and SIRPα have entered multiple clinical trials and provided anecdotal evidence for efficacy in some cancers (Advani et al., 2018; Sikic et al., 2019; Ansell et al., 2021; Querfeld et al., 2021; Son et al., 2022; Zeidan et al., 2022).